세계의 폐암 스크리닝 시장 예측(-2030년) : 암 유형별, 진단 유형별, 연령대별, 최종사용자별, 지역별 분석

According to Stratistics MRC, the Global Lung Cancer Screening Market is accounted for $3.4 billion in 2023 and is expected to reach $6.8 billion by 2030 growing at a CAGR of 10.1% during the forecast period. Lung cancer screening involves diagnostic tests to detect lung cancer in its early stages, typically through low-dose computed tomography (LDCT) scans. It is used for individuals at high risk, such as heavy smokers. Early detection allows for timely intervention, improving treatment outcomes.

According to the American Society of Clinical Oncology (2020), lung cancer is the second most common cancer in women and men is estimated to affect over 235,000 adults in the U.S in the year 2020.

Market Dynamics:

Driver:

Rising patient demand for preventive healthcare

With a growing awareness of the benefits of early detection, patients are actively seeking preventive measures, including routine screenings, to detect potential health risks such as lung cancer at an early and more treatable stage. The paradigm shift towards proactive health management, fueled by education and awareness campaigns, aligns with the rising emphasis on preventive care. As individuals prioritize their well-being and opt for preventive healthcare measures, the demand for accessible and comprehensive lung cancer screening services rises, driving the expansion and integration of screening programs into routine healthcare practices.

Restraint:

Risk of false positives

While screening programs aim to detect potential cases early, the inherent risk of false positives can lead to unnecessary anxiety, follow-up procedures, and invasive interventions. False positives can result from benign conditions or non-cancerous anomalies being detected as potentially cancerous, complicating patient experiences and potentially causing psychological distress. Beyond the emotional toll on individuals, false positives can lead to additional healthcare costs and resource utilization for follow-up tests and unnecessary treatments.

Opportunity:

Government initiatives and funding

Supportive policies and financial backing from governmental bodies enhance the accessibility and affordability of screening programs, encouraging widespread adoption. As governments recognize the societal and economic benefits of early cancer detection, they are increasingly investing in initiatives that promote lung cancer screening awareness and implementation. Funding can facilitate research, technological advancements, and the establishment of screening infrastructure. Collaborative efforts between public health agencies, healthcare providers, and policymakers contribute to the development of effective screening programs, making preventive measures accessible to a broader population.

Threat:

Radiation exposure concerns

While screening, particularly through computed tomography (CT) scans, provides valuable diagnostic information, it raises apprehensions about potential radiation-induced health risks. The cumulative exposure from frequent screenings poses a challenge, as ionizing radiation is associated with an increased risk of cancer development. Balancing the benefits of early cancer detection with the potential harm from radiation exposure is a critical consideration. Efforts to minimize radiation doses, such as the use of low-dose CT scans, are underway to address these concerns. However, the perceived risk may still deter individuals from participating in screening programs, hindering the broader adoption of lung cancer screenings.

COVID-19 Impact:

The COVID-19 pandemic has impacted the market profoundly. Disruptions in healthcare services, reallocation of resources, and concerns about virus transmission have led to a decline in routine screenings. Delays in screening and diagnosis may result in the identification of lung cancer at later stages, affecting treatment outcomes. Additionally, the focus on COVID-19 response has redirected attention and resources away from preventive healthcare initiatives. As healthcare systems adapt to pandemic challenges, there is a need for strategies to resume and prioritize lung cancer screening efforts, ensuring the continued provision of timely and effective preventive healthcare services.

The x-ray segment is expected to be the largest during the forecast period

Over the projection period, it is predicted that the x-ray segment will experience a larger market size, providing a cost-effective and widely accessible diagnostic tool. While not as sensitive as computed tomography (CT) scans, X-rays play a crucial role in initial screenings, aiding in the detection of lung abnormalities. Portable chest X-rays are commonly used to identify early signs of lung cancer, particularly in high-risk populations. The ease of X-ray implementation contributes to its widespread adoption, facilitating routine screenings and early interventions, thus enhancing the overall effectiveness of lung cancer screening programs.

The hospitals segment is expected to have the highest CAGR during the forecast period

During the forecast period, it is expected that the hospitals segment will experience lucrative growth. Equipped with advanced imaging technologies such as CT scans and X-rays, hospitals facilitate comprehensive and accurate lung cancer screenings. Their multidisciplinary teams, including pulmonologists and radiologists, ensure a holistic approach to diagnosis and subsequent care. Hospitals play a crucial role in managing screenings, from risk assessment to result interpretation, and serve as key points for coordinating follow-up care and interventions. As centralized healthcare institutions, hospitals contribute significantly to the accessibility and effectiveness of lung cancer screening initiatives.

Region with largest share:

The North America region is expected to witness largest market share, driven by a robust healthcare infrastructure, increasing awareness of preventive healthcare, and a high prevalence of lung cancer. Well-established screening programs and advanced medical technologies contribute to early detection efforts. Supportive government policies and the proactive approach of healthcare organizations enhance accessibility to screening services. The region's emphasis on early diagnosis, coupled with a rising patient demand for preventive measures, positions North America at the forefront of lung cancer screening initiatives, fostering innovation and shaping the trajectory of the global lung cancer screening market.

Region with highest CAGR:

During the forecast period, a rapid growth rate is anticipated in the Asia-Pacific region. The region's expanding population, coupled with a growing prevalence of lung cancer, underscores the demand for screening services. Government initiatives, coupled with the adoption of advanced medical technologies, contribute to the market's growth. As healthcare systems in countries like China and India prioritize early detection, the lung cancer screening market in Asia Pacific is witnessing significant development, reflecting a proactive approach to address the increasing burden of lung cancer in the region.

Key players in the market:

Some of the key players in Lung Cancer Screening market include FUJIFILM Holdings Corporation, GE Healthcare, Siemens Healthineers AG, Canon Medical Systems Corporation, Koninklijke Philips N.V., Medtronic, Nuance Communications, Inc., PenRad Technologies, Inc. and Volpara Solutions Limited.

Key Developments:

In August 2022, PenRad, a company that develops software to increase efficiency for breast imaging and lung screening, was acquired by Intelerad, a major international provider of enterprise medical imaging solutions. The purchase broadens Intelerad's product lines for lung analytics and mammography, enabling radiologists, technicians, and other healthcare workers to work more efficiently and fulfill increased demand for cancer screening while enhancing patient care.

In April 2023, Centers for Medicare & Medicaid Services (CMS) released a national coverage determination (NCD) that broadens coverage for lung cancer screening with Low Dose Computed Tomography (LDCT), to enhance health outcomes for those who have lung cancer,. In the U.S., lung cancer is one of the most prevalent malignancies and main reason for cancer-related mortality in both men and women.

Cancer Types Covered:

• Non-small Cell Lung Cancer (NSCLC)
• Small Cell Lung Cancer
• Other Cancer Types

Diagnosis Types Covered:

• Low-dose computed tomography (LDCT)
• X-ray
• Other Diagnosis Types

Age Groups Covered:

• Below 50
• 50 and older

End Users Covered:

• Hospitals
• Diagnostic Centers
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 End User Analysis
• 3.7 Emerging Markets
• 3.8 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Lung Cancer Screening Market, By Cancer Type

• 5.1 Introduction
• 5.2 Non-small Cell Lung Cancer (NSCLC)
• 5.3 Small Cell Lung Cancer
• 5.4 Other Cancer Types

6 Global Lung Cancer Screening Market, By Diagnosis Type

• 6.1 Introduction
• 6.2 Low-dose computed tomography (LDCT)
• 6.3 X-ray
• 6.4 Other Diagnosis Types

7 Global Lung Cancer Screening Market, By Age Group

• 7.1 Introduction
• 7.2 Below 50
• 7.3 50 and older

8 Global Lung Cancer Screening Market, By End User

• 8.1 Introduction
• 8.2 Hospitals
• 8.3 Diagnostic Centers
• 8.4 Other End Users

9 Global Lung Cancer Screening Market, By Geography

• 9.1 Introduction
• 9.2 North America
  • 9.2.1 US
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 Italy
  • 9.3.4 France
  • 9.3.5 Spain
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 New Zealand
  • 9.4.6 South Korea
  • 9.4.7 Rest of Asia Pacific
• 9.5 South America
  • 9.5.1 Argentina
  • 9.5.2 Brazil
  • 9.5.3 Chile
  • 9.5.4 Rest of South America
• 9.6 Middle East & Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 UAE
  • 9.6.3 Qatar
  • 9.6.4 South Africa
  • 9.6.5 Rest of Middle East & Africa

10 Key Developments

• 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 10.2 Acquisitions & Mergers
• 10.3 New Product Launch
• 10.4 Expansions
• 10.5 Other Key Strategies

11 Company Profiling

• 11.1 FUJIFILM Holdings Corporation
• 11.2 GE Healthcare
• 11.3 Siemens Healthineers AG
• 11.4 Canon Medical Systems Corporation
• 11.5 Koninklijke Philips N.V.
• 11.6 Medtronic
• 11.7 Nuance Communications, Inc.
• 11.8 PenRad Technologies, Inc.
• 11.9 Volpara Solutions Limited.